HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.

AuthorsKoji Sasaki, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Koichi Takahashi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia-Manero, William Wierda, Naval Daver, Preetesh Jain, Toshihisa Satta, Sherry Pierce, May Beth Rios, Jorge E Cortes
JournalHaematologica (Haematologica) Vol. 101 Issue 8 Pg. e324-7 (08 2016) ISSN: 1592-8721 [Electronic] Italy
PMID27175025 (Publication Type: Comparative Study, Letter)
Chemical References
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • nilotinib
  • Dasatinib
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Dasatinib (therapeutic use)
  • Humans
  • Imatinib Mesylate (pharmacology, therapeutic use)
  • Leukemia, Myeloid, Chronic-Phase (drug therapy, mortality)
  • Middle Aged
  • Propensity Score
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyrimidines (therapeutic use)
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: